Breast Cancer: Current Research
Open Access

Berberine Inhibits c-Jun Phosphorylation in Breast Cancer Cells to Suppress Fibronectin Expression

Received Date: Feb 01, 2024 / Published Date: Feb 27, 2024

Warning: Undefined variable $i in /efsdata/omicsonline.org/httpdocs/peer-reviewed/abstract-page.php on line 156

Warning: Undefined variable $for_cr in /efsdata/omicsonline.org/httpdocs/peer-reviewed/abstract-page.php on line 156
Copyright: © 0  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF

Breast cancer remains a significant global health challenge, necessitating the exploration of novel therapeutic strategies. Berberine, a natural alkaloid compound, has emerged as a promising candidate due to its diverse pharmacological activities, including anti-cancer effects. This article discusses recent research elucidating the mechanism by which berberine inhibits c-Jun phosphorylation and suppresses fibronectin expression in breast cancer cells. Activation of c-Jun and subsequent upregulation of fibronectin have been implicated in tumor progression and metastasis. The study reveals that berberine treatment effectively inhibits c-Jun phosphorylation, leading to a reduction in fibronectin expression and impairing the migratory and invasive potential of breast cancer cells. These findings highlight berberine’s potential as a therapeutic agent for breast cancer management by targeting key signaling pathways involved in tumor progression and metastasis. Further research is warranted to validate these findings and elucidate berberine’s full therapeutic potential in breast cancer therapy.

Keywords